Recent international open, which belongs to the researchers from the University of Melbourne and Harvard medical school, can greatly improve the treatment and slow down the progression of COPD (chronic obstructive pulmonary disease), which includes an incurable condition emphysema.
COPD is a progressive disease in which difficulty breathing person and caused mainly by excessive Smoking. Approximately 2.1 million Australians have some form of COPD. Projected statistics, without proper treatment by 2050 this figure will more than double to 4.5 million people.
An international team of researchers has determined that a special protein SAA plays a key role in chronic inflammation and lung damage in COPD, and also suppresses the natural effort of the lungs, which restores the body after Smoking.
The results were published in the prestigious scientific journal "proceedings of the National Academy of Sciences.
Professor Gary Anderson of the University of Melbourne said that this discovery could be a useful form of treatment to improve lung function at any stage of COPD. "It has the potential to greatly improve the lives of many people suffering from this disease and to reduce the huge burden of medical and hospital costs associated with treating patients," he said. The study's lead author Professor Stephen Bozinovski from the University of Melbourne said that the conclusions of the team of scientists were very significant.
Researchers offered a comprehensive treatment, which can also increase the effectiveness of steroids for the treatment of COPD, which in turn are effective in the treatment of other lung diseases such as asthma.
"Previously, it was assumed that steroids can work in certain conditions of disease by stopping the production of inflammatory substances, however, our research shows that steroids actually are not able to effectively block the production of inflammatory substances and, therefore, inflammation of the lungs," said Professor Gary Anderson.
Read also: Smoking causes COPD
There is hope that a new treatment will be a clinical trial in the next seven years.